A novel combination of mRNA technology and immune modulation may offer a new strategy for treating allergic diseases, according to new research demonstrating enhanced immune tolerance and reduced allergic inflammation in a preclinical model.
Moving Beyond Symptom Control
Current allergy treatments often focus on managing symptoms or reducing exposure to triggers. However, researchers are increasingly exploring ways to retrain the immune system itself to tolerate allergens.
In the new study, investigators tested an allergen-specific messenger RNA-lipid nanoparticle (mRNA-LNP) therapy designed to alter immune responses to allergens. The approach was evaluated alone and in combination with an inhibitor of the mechanistic target of rapamycin (mTOR), a key regulator of immune cell function.
Promoting Immune Tolerance
The mRNA-LNP vaccine alone stimulated immune pathways associated with protection against allergic disease, including T helper 1 and cytotoxic T-cell responses that counterbalance allergy-driving T helper 2 activity.
When combined with mTOR inhibition, however, the immune response shifted further toward tolerance. Researchers observed a substantial increase in functional regulatory T cells (Tregs), which play a critical role in suppressing excessive immune reactions and maintaining immune balance.
Reduced Signs of Allergic Asthma
In a mouse model of allergic asthma, the combination strategy maintained the anti-allergic benefits of the mRNA therapy while reducing markers of eosinophil activation, a hallmark of allergic inflammation.
The treatment also limited airway inflammation and other features associated with allergic disease.
Potential Safety Advantages
An additional benefit was a reduction in vaccine-associated cytotoxicity. The combination approach dampened some of the inflammatory immune responses seen with mRNA-LNP therapy alone while preserving its therapeutic effects.
This suggests that mTOR inhibition may help fine-tune immune responses, potentially improving both efficacy and safety.
A New Frontier for Allergy Treatment
The findings highlight the growing potential of mRNA-based therapies beyond infectious diseases. By promoting allergen-specific immune tolerance rather than simply suppressing symptoms, the approach could represent a new direction in the treatment of asthma and other allergic conditions.
While the results are currently limited to preclinical studies, the researchers believe that combining mRNA therapies with immune-regulating strategies could eventually provide more durable control of allergic and inflammatory diseases.
Reference
Rochman Y et al. Antigen-Specific mRNA–LNP Therapy with mTOR Inhibition Promotes Treg Cells and Limits Allergy. Journal of Allergy and Clinical Immunology. 2026;DOI:10.1016/j.jaci.2026.05.023.
- Author:
